Disrupting Drug Discovery: Combining Quantum Electrochemistry and AI | Partnering with Oxford University | Why Second-Time Founders Have a Unique Edge | The Importance of Boldness and Patience with Diego Stone, CEO @ Qnity | Ep 2

Investors don’t care how fancy your tech is.

Diego is the CEO of Qnity, a pharmatech startup that uses quantum electrochemistry to develop devices for drug discovery and screening. In this episode, we discuss his lessons as a second-time founder and his insights on fundraising in the deeptech space.

Topics in this episode

0:00 Intro
1:26 How Was Qnity Founded?
3:58 What Is Krilltech?
7:39 What Is Smart Money?
9:12 How to Talk About Deeptech to Investors
16:27 How to Build a Product Roadmap
22:49 Creating Interest and Managing Investor Objections
28:15 Advice for Deeptech Founders
31:31 Partnering with Oxford University
34:45 Marketing Strategies for Deeptech Startups
38:51 Understanding the Drug Discovery Market
41:37 Inside Qnity's Fundraising Journey
44:15 Expanding the Team
45:27 Fundraising Milestones for a Seed Round
48:22 Challenges in Building Client Relationships
50:08 How to Find the Right Capital for Your Startup
51:55 The Most Important Trait of a Deeptech Founder
57:29 What's Next for Qnity?

Connect with Diego on LinkedIn https://www.linkedin.com/in/diegostoneaires/?originalSubdomain=br
Follow Qnity on LinkedIn https://www.linkedin.com/company/qnity/posts/?feedView=all
Visit Qnity’s Website http://qnity.bio/

Connect with JP Orlov on LinkedIn https://www.linkedin.com/in/jp-orlov/
Follow Science VC on LinkedIn https://www.linkedin.com/company/science-vc
Follow Science VC on Instagram https://www.instagram.com/science.vc

Subscribe to Science VC on YouTube https://www.youtube.com/@ScienceVC
Subscribe to our Newsletter https://substack.com/@jporlov

Learn how WeArePalta can help your deeptech company communicate its science and impact https://www.wearepalta.com/